{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:32:03Z","timestamp":1790011923648,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.14283\/jpad.2024.110","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T08:35:10Z","timestamp":1717749310000},"page":"1198-1205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer's Disease-Modifying Therapy"],"prefix":"10.1016","volume":"11","author":[{"given":"M.","family":"Manjavong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Ashford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Eichenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Aaronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mackin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Tank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Nosheny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.14283\/jpad.2024.110_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer's disease","volume":"25","author":"Lane","year":"2018","journal-title":"European Journal of Neurology"},{"key":"10.14283\/jpad.2024.110_bib2","unstructured":"Prince M, Albanese E, Guerchet M, Prina M. World Alzheimer Report 2014: Dementia and Risk Reduction. An Analysis of Protective and Modifiable Factors2014."},{"issue":"1","key":"10.14283\/jpad.2024.110_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/JAD-131862","article-title":"Natural history of functional decline in Alzheimer's disease: a systematic review","volume":"40","author":"Delva","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"10.14283\/jpad.2024.110_bib4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"10","key":"10.14283\/jpad.2024.110_bib5","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of Aducanumab for Alzheimer Disease\u2014The FDA's Perspective","volume":"181","author":"Dunn","year":"2021","journal-title":"JAMA Internal Medicine"},{"issue":"6","key":"10.14283\/jpad.2024.110_bib6","first-page":"495","article-title":"Alzheimer Drug Lecanemab Gains Traditional FDA Approval","volume":"330","author":"Harris","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.14283\/jpad.2024.110_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.14283\/jpad.2024.110_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-018-0444-1","article-title":"Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundacio ACE Healthy Brain Initiative (FACEHBI)","volume":"10","author":"de Rojas","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"15","key":"10.14283\/jpad.2024.110_bib9","doi-asserted-by":"crossref","first-page":"e1580","DOI":"10.1212\/WNL.0000000000009240","article-title":"Total A\u03b242\/A\u03b240 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis","volume":"94","author":"Doecke","year":"2020","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.110_bib10","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma beta-amyloid in Alzheimer's disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci Rep"},{"issue":"8","key":"10.14283\/jpad.2024.110_bib11","doi-asserted-by":"crossref","first-page":"e14398","DOI":"10.15252\/emmm.202114398","article-title":"Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers","volume":"13","author":"Ossenkoppele","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.14283\/jpad.2024.110_bib12","author":"Xiong"},{"issue":"6","key":"10.14283\/jpad.2024.110_bib13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp-2022-330619","article-title":"Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic","volume":"94","author":"Altomare","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.14283\/jpad.2024.110_bib14","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease","volume":"17","author":"Simren","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2024.110_bib15","author":"Zabala-Findlay"},{"issue":"2","key":"10.14283\/jpad.2024.110_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13205-022-03123-4","article-title":"Hippocampus and its involvement in Alzheimer's disease: a review","volume":"12","author":"Rao","year":"2022","journal-title":"3 Biotech"},{"issue":"1","key":"10.14283\/jpad.2024.110_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13195-018-0395-6","article-title":"Plasma amyloid-\u03b2 levels, cerebral atrophy and risk of dementia: a population-based study","volume":"10","author":"Hilal","year":"2018","journal-title":"Alzheimer's Research & Therapy"},{"issue":"1","key":"10.14283\/jpad.2024.110_bib18","doi-asserted-by":"crossref","first-page":"e12396","DOI":"10.1002\/dad2.12396","article-title":"Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease","volume":"15","author":"Chong","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"issue":"13","key":"10.14283\/jpad.2024.110_bib19","doi-asserted-by":"crossref","first-page":"e1315","DOI":"10.1212\/WNL.0000000000200035","article-title":"Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline","volume":"98","author":"Ebenau","year":"2022","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.110_bib20","author":"Tsai"},{"key":"10.14283\/jpad.2024.110_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"10.14283\/jpad.2024.110_bib22","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1212\/WNL.0000000000011214","article-title":"Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation","volume":"96","author":"Farrell","year":"2021","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.110_bib23","doi-asserted-by":"crossref","first-page":"102804","DOI":"10.1016\/j.nicl.2021.102804","article-title":"Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer's disease","volume":"32","author":"Contador","year":"2021","journal-title":"Neuroimage Clin"},{"issue":"12","key":"10.14283\/jpad.2024.110_bib24","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/alz.12353","article-title":"Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease","volume":"17","author":"Libiger","year":"2021","journal-title":"Alzheimer's & Dementia"},{"key":"10.14283\/jpad.2024.110_bib25","author":"Zicha"},{"issue":"8","key":"10.14283\/jpad.2024.110_bib26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.14283\/jpad.2024.110_bib27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.14283\/jpad.2024.110_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v098.i11","article-title":"cutpointr: Improved Estimation and Validation of Optimal Cutpoints in R","volume":"98","author":"Thiele","year":"2021","journal-title":"Journal of Statistical Software"},{"issue":"17","key":"10.14283\/jpad.2024.110_bib29","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.14283\/jpad.2024.110_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.14283\/jpad.2018.41","article-title":"Plasma Abeta42\/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study","volume":"6","author":"Perez-Grijalba","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"10.14283\/jpad.2024.110_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2967\/jnumed.122.264279","article-title":"A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer's Disease Continuum","volume":"64","author":"Coomans","year":"2023","journal-title":"Journal of Nuclear Medicine"},{"issue":"4","key":"10.14283\/jpad.2024.110_bib32","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/alz.12751","article-title":"An accurate fully automated panel of plasma biomarkers for Alzheimer's disease","volume":"19","author":"Palmqvist","year":"2023","journal-title":"Alzheimer's & Dementia"},{"key":"10.14283\/jpad.2024.110_bib33","doi-asserted-by":"crossref","first-page":"1150510","DOI":"10.3389\/fnagi.2023.1150510","article-title":"Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer's disease","volume":"15","author":"Zhang","year":"2023","journal-title":"Front Aging Neurosci"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:14:24Z","timestamp":1737339264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724006484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2274580724006484"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.110","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer's Disease-Modifying Therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}